Intrexon: Chimeras, CRSPR and Gene Therapy – Moneyshow.com (registration)
|
Intrexon: Chimeras, CRSPR and Gene Therapy
Moneyshow.com (registration) Intrexon (XON) has made a small yet strategic acquisition in buying GenVec (GNVC); with the purchase, XON gets AdenoVerse, a platform of adenovirus vectors for delivering drugs and vaccines that dovetails nicely with its existing suite of gene therapy … |
